Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PHE885 BCMA CAR-T in relapsed/refractory multiple myeloma (Japan)
jRCT2013220012Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of durcabtagene autoleucel in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Response according to IMWG criteria. Started Aug 2022; status: completed.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2013220012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013220012.